Boston Scientific, an industry leader in electrophysiology, has signed a definitive agreement to acquire Cortex, an Ajax Health company with a precise diagnostic mapping technology that complements Boston’s PFA therapeutic solutions. Read more: https://lnkd.in/dVbcBkGY
Cortex
医疗设备制造业
Santa Clara,CA 8,284 位关注者
Cortex aims to transform diagnosis and treatment of AF with insight into each individual’s disease pathophysiology.
关于我们
Cortex aims to transform the diagnosis and treatment of atrial arrhythmias by providing insight into each individual patient’s disease pathophysiology. The OptiMap? System is a 510k cleared, electrographic flow mapping solution designed with AI, enabling physicians to?See What Matters.
- 网站
-
CortexEP.com
Cortex的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Santa Clara,CA
- 类型
- 私人持股
- 创立
- 2023
- 领域
- Medical Device、Machine Learning、Deep Learning、MedTech、Atrial Fibrillation、Pulsed Field Ablation和Electrophysiology
地点
-
主要
US,CA,Santa Clara
Cortex员工
动态
-
Cortex转发了
Boston Scientific will acquire Ajax Health's Cortex and its FDA-cleared OptiMap system to guide physicians performing ablation procedures to treat #AFib. ?“Joining Boston Scientific will allow us to further develop this technology, which we believe has the ability to transform the treatment of AF for patients around the world.” Find out more at MassDevice. #cardiology #pulsedfieldablation #mergersandacquisitions #medtech #meddevice
-
Cortex转发了
I love how Boston Scientific continues to accelerate around the curve in electrophysiology. The move to add Cortex during their record-breaking year shows they are playing every card to win. When the dust settles on the paradigm shift happening in EP, I'm confident they will be standing at the top of the podium. And that will be very, very soon! Mike Mahoney, Joe Fitzgerald, Ken Stein, and Nick Spadea-Anello are part of a world-class ELT that is leading Boston Scientific to new realms. They are driving a $120 billion, market-leading company with the same entrepreneurial fire that drives our small Cortex and Ajax Health teams. And in the process, they are breaking down decades-old efficacy boundaries — and patients will be the beneficiaries of their work. GAME RESPECT GAME!
We are excited to announce that Boston Scientific has entered into a definitive agreement to acquire Cortex, developers of the OptiMap? System. This advanced diagnostic mapping solution offers valuable insight into the unique individual disease pathophysiology for patients with persistent atrial fibrillation.? The addition of Cortex into our Electrophysiology portfolio will expand our ability to offer clinically differentiated mapping solutions to physicians and the patients they serve. This acquisition will enable us to deliver a more comprehensive range of solutions for electrophysiologists, with intentions to drive better outcomes for patients. We continue to focus on differentiating technology that can lead to more meaningful advancements in patient care. Read more in our press release: https://lnkd.in/gfUutbMY #PulsedFieldAblation #CardiacMapping #MedTech #Innovation??
-
Congratulations to Neuron Medical Hospital in Czech Republic, which has completed their enrollment for RESOLVE-AF! We’re grateful for the consistent support of Dr. Martin Fiala (principal investigator), Dr. Franti?ek Lehar, Dr. Michal ?erno?ek and Dr. Ji?í Je?, who performed cases, Veronika Bulkova, study coordinator at the site, and Pavel Sima, who supported the cases on our behalf. RESOLVE-AF is a large, prospective, multi-national trial evaluating the use of the OptiMap? System to perform Electrographic Flow??mapping to identify extra-pulmonary vein sources and See What Matters. Visit?www.CortexEp.com?to learn more about the OptiMap System. #EPeeps?#EP?#AF?#Afib
-
We’re excited to have Dr. Ahmed F. Osman of Florida Heart Rhythm Specialists, PLLC. join the RESOLVE-AF trial by completing his first case last week along with Clinical Research Coordinator Carlos Guadamas and our own Kristin Brown. Thanks to the EP lab staff at?HCA Florida Westside Hospital?and Dr. David Kenigsberg, the principal investigator at the site, for their continued support of this trial. ? RESOLVE-AF is a large, prospective, multi-national trial evaluating the use of the OptiMap? System to perform Electrographic Flow??mapping to identify extra-pulmonary vein sources and See What Matters. Visit?www.CortexEp.com?to learn more about the OptiMap System. #EPeeps?#EP?#AF?#Afib
-
Cortex转发了
Big thanks to Dr. #Tom De Potter and his team at OLV Hospital Aalst for their continued support of the #Cortex OptiMap System and the RESOLVE-AF Clinical Trial!?We are also excited about enrolling patients at more Belgian Sites soon. Big shout out to #Kristin Brown for traveling to Aalst to provide excellent clinical support.
-
Congratulations to David Kenigsberg, MD, FHRS and his colleagues at HCA Florida Westside Hospital for completing their first case in the RESOLVE-AF trial! ? RESOLVE-AF is a large, prospective, multi-national trial evaluating the use of the OptiMap? System to perform Electrographic Flow??mapping to identify extra-pulmonary vein sources and See What Matters. Visit?www.CortexEp.com to learn more about the OptiMap System. #EPeeps?#EP?#AF?#Afib
-
Cortex转发了
Please to announce that we successfully completed our first #PersAF patient enrolled in the Cortex RESOLVE-AF Trial: A prospective, single arm, multi-center, clinical evaluation of the Ablacath? Mapping Catheter and Ablamap? System utilizing Electrographic Flow (EGF) mapping to resolve extra-pulmonary vein sources of Atrial Fibrillation and guide ablation therapy at HCA Florida Westside Hospital #epeeps Carlos Guadamas Melissa H. Kong, MD Duke Rohlen Sarah Parish Kristin Brown Florida Heart Rhythm Specialists, PLLC.
-
We're #hiring a new Field Clinical Engineer in the United States. Join our team as we aim to transform diagnosis and treatment of AF with insight into each individual’s disease pathophysiology that helps physicians See What Matters.
-
Cortex转发了
The optimal ablation set beyond PVI for persistent AF patients remains undetermined. Should we go for an anatomical approach (e.g., PWI, VoM, LAAI) or does an personalized approach based on AF mapping still has a role? The randomized FLOW-AF trial demonstrated superiority of EGF-guided ablation vs PVI-only in redo cases (https://lnkd.in/eZNpduKG). The multicenter RESOLVE-AF study will evaluate whether active AF sources identified by OptiMap are clinically relevant in persistent AF patients undergoing their first PVI. This week we enrolled the first patient in the Erasmus MC for RESOLVE-AF. Excited to be part of this endeavor to establish the role of EGF mapping. Thanks to Marloes Jansen for the support. Sip Wijchers, Rohit Bhagwandien, Bakhtawar Khan Mahmoodi, Nick van Boven, Duke Rohlen, Melissa H. Kong, MD, Dr. Philip Haeusser, Erik Harks, Lucas Boersma #CORTEX, #EGF, #OptiMap